Supporting this hypothesis, Jacobsen et al. [30] recently showed that targeting EGFR can trigger compensatory activation of other ErbB family receptors, HER2 and/or HER3, and that simultaneous inhibition of EGFR, ErbB2 and ErbB3 effectively overcame tumor heterogeneity and plasticity. This evidence concerns the gene ERBB2 and neoplasm.